肿瘤免疫检查点疗法与CAR-T细胞治疗及其组合治疗策略的临床运用价值  

Clinical application of tumor immune checkpoint and chimeric antigen receptor T-cell： monotherapy and combination therapy

作　　者：李林玉[1] 张婷婷[1] 贾晓辉[1] 孔令喆 孟斌[1] 任秀宝[1] 傅凯[1] 潘嫱 王先火[1] 张会来[1] 

机构地区：[1]天津医科大学肿瘤医院淋巴瘤内科、中美淋巴血液肿瘤诊治中心、国家肿瘤临床学研究中心、天津市“肿瘤防治”重点实验室、天津市恶性肿瘤临床医学研究中心300060

出　　处：《中华微生物学和免疫学杂志》2017年第4期315-319,共5页Chinese Journal of Microbiology and Immunology

基　　金：国家自然科学基金（81402945）

摘　　要：肿瘤免疫检查点（immune checkpoint）疗法已在肿瘤治疗中取得突出进展，为晚期肿瘤患者带来了前所未有的希望。到目前为止，已有4个免疫检查点抑制剂获得FDA批准，并用于多种肿瘤的治疗。与此同时，嵌合抗原受体T细胞（chimeric antigen receptor T-cell，CAR-T）治疗在血液肿瘤中也取得了令人惊奇的疗效，这类细胞治疗有望成为更多肿瘤患者的选择。本篇综述，我们主要阐述肿瘤免疫检查点疗法和CAR-T细胞治疗的最新进展，并讨论其组合治疗策略的潜在临床运用。Outstanding progress in immune checkpoint therapy has been achieved with respect to tumor therapy, which brings unprecedented hope for patients with advanced cancer. So far, four immune checkpoint inhibitors have been approved by the Food and Drug Administration （FDA） to be used in the treatment of various tumors. Meanwhile, researchers has found that chimeric antigen receptor T-cel] （ CAR- T） therapy has significant anti-tumor effect on hematologic malignancies, which means that it is expected to be a potential choice for more patients with cancer. In this review, we focus on the latest advances in tumor immune checkpoint therapy and CAR-T therapy, and discuss the potential values of them used in combina- tion in clinical application.

关 键 词：免疫检查点 嵌合抗原受体T细胞 联合治疗 

分 类 号：R730.51[医药卫生—肿瘤]